Biomaterials for protein delivery for complex tissue healing responses

Abstract

Recent advances in biomaterial delivery vehicles have increased the ability to tailor precise protein delivery to restore normal healing cascades and stimulate robust tissue repair.

The emerging translational potential of GDF11 in chronic wound healing

“…Covalent coupling strategies can be applied when long-term protein presentation for continuous cellular responses is needed. Protein retention can be achieved using polymers such as PLGA through carbodiimide crosslinker chemical reaction, specifically through N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) coupling [ 73 ]. Wang et al.…”

Statistical optimization of hydrazone-crosslinked hyaluronic acid hydrogels for protein delivery

“…The degree of chemical modification of HA-ADH and HA-Nor was quantified using proton nuclear magnetic resonance spectroscopy ( 1 H NMR, 500 Hz, Bruker, USA). 2-5 mg of modified polymer was dissolved in 600 mL of deuterium oxide (D 2 O) for 1 H NMR (256 scans). To calculate the degree of modification for HA-ADH, the peaks from the aliphatic chain were integrated from 2.5-2.1 ppm and 1.7-1.44 ppm (8H) and normalized to the This journal is © The Royal Society of Chemistry 2024 n-acetyl methyl group peaks from 1.8-2 ppm (3H) (Fig.…”

Moderate‐Affinity Affibodies Modulate the Delivery and Bioactivity of Bone Morphogenetic Protein‐2

“…Methods to control protein release from biomaterial delivery vehicles include physical modifications such as changing the porosity or degradation rate of the delivery vehicle [13,14] and chemical modifications such as tethering proteins directly to the delivery vehicle. [15] While promising under certain conditions, these techniques often result in burst release kinetics, unpredictable protein release rates within complex in vivo environments, and inconsistent loading of the protein therapeutic, contributing to insufficient localization of the protein in the intended site and poor healing outcomes. [16] Although chemical conjugation of therapeutic proteins to biomaterials can reduce the likelihood of burst release and prolong protein presentation within the site of interest, [17] it can also interfere with protein-receptor binding, potentially altering the biological function of the therapeutic protein and resulting in reduced protein bioactivity.…”